Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
filingDate |
2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aea96214c85f8536ebefb321c5e35cd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9228cab7cb2a462bfd176c024503317c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84699776c8d588f1008b1bdd5a6a936d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17b8c8c04fcbedd86324dbcdf7723a52 |
publicationDate |
2012-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2527354-A1 |
titleOfInvention |
Compositions and methods for inhibiting expression of Eg5 gene |
abstract |
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell. |
priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |